Table 3.
[18F]-FDA | [123I]-MIBG | [123I] or [131I]-MIBG | CT | MRI | |
---|---|---|---|---|---|
Non-metastatic PHEO, per lesion analysis | |||||
Sensitivity | 78% (25/32) | 78% (21/27) | 76% (22/29) | 97% (31/32) | 92% (24/26) |
Specificity | 77% (10/13) | 92% (12/13) | 92% (12/13) | 38% (5/13) * | 58% (7/12) |
Metastatic PHEO, per patient analysis | |||||
Sensitivity | 97% (33/34) | 85% (17/20) | 65% (20/31) # | 100% (32/32) | 100% (31/31) |
P=0.039 versus [123I], and [123]/[131] MIBG
P=0.002 versus [18F]-FDA, whole body CT, and whole body MRI